 |
|
|
| |
SUBGROUP ANALYSES AND BASELINE PREDICTORS OF RESPONSE WITH FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF STARTVerso1 AND 2
|
| |
| |
Reported by Jules Levin
AASLD 2013 Nov 1-4 Wash DC
EM Yoshida1 T Asselah2, C Moreno3, M Maevskaya4, J-H Kao5, J Crespo6, J-F Dufour7, DK Wong8, E Tam9, SV Feinman10, M Schuchmann11, M Omata12, P Ferenci13, KV Kowdley14, Y-J Lee15, E Tomita16, SW Paik17, H Yatsuhashi18, JO Stern19, AM Quinson19, F Voss20, J Scherer19, Y Datsenko20, DM Jensen21, on behalf of the STARTVerso1 and STARTVerso2 Study
Groups
1University of British Columbia, Vancouver, BC, Canada; 2Hôpital Beaujon, APHP, University Paris-Diderot and INSERM CRB3, Clichy, France; 3Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium; 4First Moscow State Medical University, Moscow, Russia; 5National Taiwan University Hospital, Taipei, Taiwan; 6University Hospital Marqués de Valdecilla, Santander, Spain; 7University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 8Toronto Western Hospital Liver Center, Toronto, ON, Canada; 9LAIR Centre, Vancouver, BC, Canada; 10Hepatitis Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; 11University Hospital Mainz, Mainz, Germany; 12Yamanishi Central and Kita Hospitals, Yamanishi, Japan; 13Medical University of Vienna, Vienna, Austria; 14Virginia Mason Medical Center, Seattle, WA, USA; 15Inje University Busan Paik Hospital, Busan, South Korea; 16Gifu Municipal Hospital, Gifu, Japan; 17Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 18Nagasaki Medical Centre, Nagasaki, Japan; 19Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 20Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; 21University of Chicago Medicine, Chicago, IL, USA
|
| |
|
|
|
|
|
